Drug Delivery
EXECUTIVE INTERVIEW – Agere: Solubilization: Accessing Broader Chemistries by Integrating Fundamental Science With Automation for Greater Predictability
Drug Development Executive: Marshall Crew, President & CEO of Agere, discusses how the company is taking a different approach that leverages expertise, but relies heavily on the principles of physical chemistry to enable automation.
FORMULATION DEVELOPMENT – Bioavailability Enhancement Strategies & Opportunities
Frost & Sullivan Analyst Ruplekha Choudhurie reviews some BA approaches that are being developed by a number of companies that can mitigate the biological, physical, and chemical barriers for effective delivery of poorly soluble and permeable drugs.
DRUG DELIVERY – Oral Delivery of Peptides by Peptelligence Technology
William Stern, PhD; Nozer Mehta, PhD; and Stephen Carl, PhD; review a highly developed, clinically proven platform technology that enables the oral delivery of peptides, overcoming the hurdles inherent to oral peptide delivery.
DRUG DEVICES – Intranasal Saline: Can a Spray Per Day Keep the Doctor Away?
Degenhard Marx, PhD, and Georges Bouille provide an overview and discussion of the benefits of using intranasal saline, and a range of different devices on the market allowing administration into the nose.
CONTRACT SERVICES – Maximizing Yield in Transdermal Manufacturing
James Fenton says that while the challenges presented by manufacturing pain management products can be significant for some manufacturers, for the right manufacturer, pain management products can present an ideal opportunity.
DELIVERY DEVICES – The New Industry Paradigm for Prefilled Success
Alan Shortall indicates that following a period of relative industry stability defined by peripheral innovation, a converging series of external and internal forces are set to reshape the prefilled syringe industry so that it will better serve the emerging needs of pharmaceutical companies, patients, and other stakeholders across the continuum of care.
PLATFORM TECHNOLOGY – Tumor-Targeting Platform Delivers the Next Generation of Pediatric Cancer Drugs
Contributor Cindy H. Dubin examines the desperate need for therapies that can address underserved populations, eradicate the cancer state without severe complications, and prolong the lifespan of the patient after diagnosis, and how NanoSmart Pharmaceuticals, with its unique tumor-targeting platform, has taken on that challenge.
DRUG DELIVERY – HEPtune: A Process of Conjugating a Naturally Occurring Sugar Molecule, Heparosan, to a Drug for Enhanced Drug Delivery
Paul L. DeAngelis, PhD, shows how heparosan is a stealthy molecule well suited for use as a drug delivery vehicle due to its natural origin and properties in the body. Therefore, heparosan-modified therapeutics may offer improved pharmacokinetics, drug performance properties, as well as new options for treatment and hope for patients.
EXECUTIVE INTERVIEW – Aptalis Pharmaceutical Technologies: Patient Centric Drug Delivery
Robert Becker, PhD, Chief Research Officer at Aptalis Pharma, discusses Patient Centric Drug Delivery and the company’s role in supporting patient compliance and driving commercial value through new drug formulations.
DRUG DELIVERY – EyeSol: a Novel Topical Ocular Drug Delivery System for Poorly Soluble Drugs
Dieter Scherer, PhD; Eva Alvarez-Gonzalez, PhD; and Anthony Pettigrew, MSc; examine a proprietary non-protic, aqueous-free ocular delivery system with the potential to provide an alternative approach in particular for poorly soluble drugs.
EXCLUSIVE ONLINE CONTENT

Radius Health Announces Commercial Agreement With Paladin Labs
Radius Health, Inc. recently announced it has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc to register, commercialize, and distribute abaloparatide on an exclusive basis in….

Vectura Earns $11-Million Milestone as Hikma Receives US FDA Approval for Generic Advair DiskusR
Vectura Group plc recently announced its partner Hikma Pharmaceuticals has launched its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder)….

Gattefossé Continues International Development & Builds Production Site in Texas
Gattefossé is investing 30 million euros in its industrial operations and announced the construction of a brand new manufacturing plant in Lufkin, TX. This asset will produce lipid-based….

New Clinical Trial Data Demonstrates BD Libertas Wearable Injector as a Drug Delivery System
BD (Becton, Dickinson and Company) recently announced publication of the results from a 52-subject human clinical trial with the BD Libertas Wearable Injector…..

Vectura Signs Development Agreement With Kinaset Therapeutics
Vectura Group plc recently announced it has signed a global outlicense and development agreement with Kinaset Therapeutics Inc. for the development and commercialization of….